Share Statistics Avg Vol (3 month)3: 6,387,060 Avg Vol (10 day)3: 38,413,000 Shares Outstanding5: 38.41M Float: 37.92M % Held by Insiders1: 1.89% % Held by Institutions1: 2.90% Shares Short (as of Mar 14, 2014)3: 2.28M Short Ratio (as of Mar 14, 2014)3: 1.70 Short % of Float (as of Mar 14, 2014)3: 6.10% Shares Short (prior month)3: 1.70M
IsoRay Medical™ utilizes proprietary technologies to deliver novel brachytherapy approaches to clinicians. IsoRay's Cesium-131 isotope has been used as primary treatment for prostate cancer in over 7,000 patients. As adjuvant radiation therapy, Cesium-131 is being employed in the management of non-small cell lung cancer, intra-cranial tumors (including meningiomas), and head & neck malignancies post-surgical resection.
Additionally, Cesium-131 is currently being used as monotherapy in the management of gynecologic recurrences and ocular melanomas Customized strands, meshes, and applicators are available bearing Cesium-131 sources, and the recently reintroduced GliaSite Radiation Therapy System is available for brachytherapy of the resection bed following surgical removal of gliomas and brain metastases.
•IsoRay, Inc. Closes $14,675,180 Registered Direct Offering March 27, 2014 •IsoRay Prices Registered Direct Offering of Common Stock March 21, 2014 •IsoRay Announces Greek Governmental Approval for Sales of It’s Entire Product Line March 11, 2014 •IsoRay, Inc Reports Second Quarter Results February 18, 2014 •IsoRay Receives Five Year CE Mark Extension for All Cesium-131 Seed Products January 29, 2014
2014 Events just for April...
ABS American Brachytherapy Society 2014 ABS Annual Meeting April 3th – April 5th, 2014 Manchester Grand Hyatt San Diego, CA Visit us at booth 301
AANS American Association of Neuro Surgeons 2014 82nd AANS Annual Scientific Meeting April 7th – April 9th, 2014 Moscone Center San Francisco, CA
AATS American Association for Thoracic Surgery 2014 AATS 94th Annual Meeting April 26th – April 30th, 2014 Toronto, Canada
HOD 3.14, riding free.
Day's Range 2.85 - 3.47
mighta settled down a bit. Still keeping some freebies.
IsoRay Has Tremendous Potential Gaining More Published Peer Reviews
This is exactly what I have been hitting on for the last couple weeks. I see there's some consensus at least. smile
When it comes to emerging companies like IsoRay one major obstacle though is funding. But here again, IsoRay is in a solid position. Babcock told us that the company has around $20 million in cash on its balance sheet, which at the current burn rate is sufficient to last for eight years. When asked whether the company will look to capitalize on the surge in share price this year by coming out with a secondary offering, Babcock said that there is no immediate need for such an offering. However, he added that the company would always like to be in a strong cash position, especially if it considers a synergistic acquisition in the future.